Teachers Retirement System of The State of Kentucky Sells 1,110 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Teachers Retirement System of The State of Kentucky lowered its position in Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 2.5% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 42,911 shares of the biopharmaceutical company’s stock after selling 1,110 shares during the period. Teachers Retirement System of The State of Kentucky’s holdings in Halozyme Therapeutics were worth $2,456,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also modified their holdings of HALO. Chiron Investment Management LLC boosted its stake in shares of Halozyme Therapeutics by 23.6% during the third quarter. Chiron Investment Management LLC now owns 23,502 shares of the biopharmaceutical company’s stock valued at $1,345,000 after purchasing an additional 4,491 shares during the period. Coldstream Capital Management Inc. lifted its holdings in Halozyme Therapeutics by 34.7% during the 3rd quarter. Coldstream Capital Management Inc. now owns 9,251 shares of the biopharmaceutical company’s stock valued at $534,000 after buying an additional 2,384 shares in the last quarter. Geode Capital Management LLC lifted its holdings in Halozyme Therapeutics by 1.0% during the 3rd quarter. Geode Capital Management LLC now owns 3,060,131 shares of the biopharmaceutical company’s stock valued at $175,194,000 after buying an additional 30,901 shares in the last quarter. M&T Bank Corp boosted its position in Halozyme Therapeutics by 0.5% in the 3rd quarter. M&T Bank Corp now owns 111,239 shares of the biopharmaceutical company’s stock valued at $6,367,000 after buying an additional 561 shares during the period. Finally, MML Investors Services LLC grew its stake in Halozyme Therapeutics by 80.7% in the 3rd quarter. MML Investors Services LLC now owns 9,779 shares of the biopharmaceutical company’s stock worth $560,000 after acquiring an additional 4,366 shares in the last quarter. Hedge funds and other institutional investors own 97.79% of the company’s stock.

Insider Activity

In related news, CEO Helen Torley sold 10,000 shares of the company’s stock in a transaction dated Wednesday, September 25th. The stock was sold at an average price of $56.34, for a total transaction of $563,400.00. Following the transaction, the chief executive officer now directly owns 676,744 shares of the company’s stock, valued at $38,127,756.96. This represents a 1.46 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. In the last quarter, insiders sold 40,000 shares of company stock worth $2,242,100. Insiders own 2.40% of the company’s stock.

Halozyme Therapeutics Trading Up 0.4 %

NASDAQ:HALO opened at $48.00 on Monday. The stock has a market capitalization of $6.11 billion, a price-to-earnings ratio of 15.89, a PEG ratio of 0.43 and a beta of 1.23. Halozyme Therapeutics, Inc. has a 52 week low of $33.15 and a 52 week high of $65.53. The company has a quick ratio of 9.15, a current ratio of 10.36 and a debt-to-equity ratio of 3.32. The firm has a 50 day moving average of $51.43 and a 200 day moving average of $54.07.

Analysts Set New Price Targets

HALO has been the subject of several research analyst reports. Piper Sandler lifted their price target on shares of Halozyme Therapeutics from $51.00 to $52.00 and gave the company a “neutral” rating in a research note on Monday, November 4th. Wells Fargo & Company cut Halozyme Therapeutics from an “overweight” rating to an “equal weight” rating and upped their target price for the stock from $58.00 to $62.00 in a report on Monday, October 7th. JMP Securities raised their price target on Halozyme Therapeutics from $72.00 to $73.00 and gave the company a “market outperform” rating in a research note on Friday, November 1st. JPMorgan Chase & Co. lowered shares of Halozyme Therapeutics from an “overweight” rating to a “neutral” rating and upped their price objective for the stock from $52.00 to $57.00 in a research note on Thursday, September 19th. Finally, Cowen reiterated a “buy” rating on shares of Halozyme Therapeutics in a report on Friday, October 18th. Four analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $61.11.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.